Takeda Pays Alnylam $20 Million For Gene-Silencing Technology
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals paid U.S.-based Alnylam Pharmaceuticals $20 million for its gene-silencing technology. The information is part of an agreement to transfer RNAi technology from Alnylam to Takeda in exchange for milestone and royalty payments by Takeda, already beyond $120 million. Takeda intends to use the information to develop treatments to block proteins before they can cause a disease or medical condition. (Click here for more